Literature DB >> 19424764

Prescribers and pharmaceutical representatives: why are we still meeting?

Melissa A Fischer1, Mary Ellen Keough, Joann L Baril, Laura Saccoccio, Kathleen M Mazor, Elissa Ladd, Ann Von Worley, Jerry H Gurwitz.   

Abstract

CONTEXT: Research suggests that pharmaceutical marketing influences prescribing and may cause cognitive dissonance for prescribers. This work has primarily been with physicians and physician-trainees. Questions remain regarding why prescribers continue to meet with pharmaceutical representatives (PRs).
OBJECTIVE: To describe the reasons that prescribers from various health professions continue to interact with PRs despite growing evidence of the influence of these interactions. DESIGN, SETTING, AND PARTICIPANTS: Multi-disciplinary focus groups with 61 participants held in practice settings and at society meetings.
RESULTS: Most prescribers participating in our focus groups believe that overall PR interactions are beneficial to patient care and practice health. They either trust the information from PRs or feel that they are equipped to evaluate it independently. Despite acknowledgement of study findings to the contrary, prescribers state that they are able to effectively manage PR interactions such that their own prescribing is not adversely impacted. Prescribers describe few specific strategies or policies for these interactions, and report that policies are not consistently implemented with all members of a clinic or institution. Some prescribers perceive an inherent contradiction between academic centers and national societies receiving money from pharmaceutical companies, and then recommending restriction at the level of the individual prescriber. Prescribers with different training backgrounds present a few novel reasons for these meetings.
CONCLUSIONS: Despite evidence that PR detailing influences prescribing, providers from several health professions continue to believe that PR interactions improve patient care, and that they can adequately evaluate and filter information presented to them by PRs. Focus group comments suggest that cultural change is necessary to break the norms that exist in many settings. Applying policies consistently, considering non-physician members of the healthcare team, working with trainees, restructuring the current primary care model and offering convenient, individualized, non-biased educational options may aid success.

Entities:  

Mesh:

Year:  2009        PMID: 19424764      PMCID: PMC2695530          DOI: 10.1007/s11606-009-0989-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  42 in total

1.  Physicians and the pharmaceutical industry: is a gift ever just a gift?

Authors:  A Wazana
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

2.  Complimentary journeys to the World Congress of Gastroenterology--an inquiry of potential sponsors and beneficiaries.

Authors:  V F Eckardt
Journal:  Z Gastroenterol       Date:  2000-01       Impact factor: 2.000

3.  Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions.

Authors:  M A Steinman; M G Shlipak; S J McPhee
Journal:  Am J Med       Date:  2001-05       Impact factor: 4.965

4.  Pharmaceutical marketing research and the prescribing physician.

Authors:  Jeremy A Greene
Journal:  Ann Intern Med       Date:  2007-05-15       Impact factor: 25.391

5.  The rosiglitazone story--lessons from an FDA Advisory Committee meeting.

Authors:  Clifford J Rosen
Journal:  N Engl J Med       Date:  2007-08-08       Impact factor: 91.245

6.  Characteristics of recipients of free prescription drug samples: a nationally representative analysis.

Authors:  Sarah L Cutrona; Steffie Woolhandler; Karen E Lasser; David H Bor; Danny McCormick; David U Himmelstein
Journal:  Am J Public Health       Date:  2008-01-02       Impact factor: 9.308

7.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

8.  Physicians and drug representatives: exploring the dynamics of the relationship.

Authors:  Susan Chimonas; Troyen A Brennan; David J Rothman
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

Review 9.  Following the script: how drug reps make friends and influence doctors.

Authors:  Adriane Fugh-Berman; Shahram Ahari
Journal:  PLoS Med       Date:  2007-04       Impact factor: 11.069

Review 10.  Soft targets: nurses and the pharmaceutical industry.

Authors:  Annemarie Jutel; David B Menkes
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more
  21 in total

1.  Is there a doctor in the house? : The presence of physicians in the direct-to-consumer genetic testing context.

Authors:  Heidi Carmen Howard; Pascal Borry
Journal:  J Community Genet       Date:  2011-09-06

2.  Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey.

Authors:  James S Yeh; Kirsten E Austad; Jessica M Franklin; Susan Chimonas; Eric G Campbell; Jerry Avorn; Aaron S Kesselheim
Journal:  J Grad Med Educ       Date:  2015-12

3.  Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

4.  Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.

Authors:  Christopher Scott Brunt
Journal:  Health Serv Res       Date:  2018-10-01       Impact factor: 3.402

5.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

6.  A randomized trial evaluating 2 approaches for promoting pharmacy-based referrals to the tobacco quitline: methods and baseline findings.

Authors:  Alan J Zillich; Robin L Corelli; Susan M Zbikowski; L Brooke Magnusson; Christine M Fenlon; Alexander V Prokhorov; Carl de Moor; Karen Suchanek Hudmon
Journal:  Res Social Adm Pharm       Date:  2012-05-02

7.  General practitioners and sales representatives: Why are we so ambivalent?

Authors:  Adriaan Barbaroux; Isabelle Pourrat; Tiphanie Bouchez
Journal:  PLoS One       Date:  2022-01-24       Impact factor: 3.240

Review 8.  Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.

Authors:  Geoffrey K Spurling; Peter R Mansfield; Brett D Montgomery; Joel Lexchin; Jenny Doust; Noordin Othman; Agnes I Vitry
Journal:  PLoS Med       Date:  2010-10-19       Impact factor: 11.069

9.  Physicians' perceptions of medical representative visits in Yemen: a qualitative study.

Authors:  Mahmoud Abdullah Al-Areefi; Mohamed Azmi Hassali; Mohamed Izham b Mohamed Ibrahim
Journal:  BMC Health Serv Res       Date:  2013-08-20       Impact factor: 2.655

10.  Attitude and practice of dental surgeons towards pharmaceutical companies' marketing gifts.

Authors:  Shaila Tahir; Adeela Rafique; Farkhanda Ghafoor; Akif Saleem; Amanullah Khan
Journal:  J Med Ethics Hist Med       Date:  2013-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.